Patent · US Active

Bispecific antibodies against CD3 and BCMA

US10077315B2 · kind B2 · utility

6Cited by

8References

5Claims

0Family size

Assignee

ENGMAB SÀRL · CH

Inventors

Minh Diem Vu · Wollerau, CH
Klaus Strein · Hemsbach, DE
Ekkehard Moessner · Kreuzlingen, CH
Ralf Hosse · Baar, CH
Oliver Ast · Bassersdorf, CH
Anne Freimoser-Grundschober · Bellinzona, CH
Marina BACAC · Schlieren, CH
Tanja Fauti · Zürich, CH
Christian Klein · Iffeldorf, DE
Pablo Umana · Wollerau, CH
Samuel Moser · Rotkreuz, CH

Key dates

Filing date	Feb 5, 2014
Grant date	Sep 18, 2018
Priority date	—
Expiry date	Apr 13, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A bispecific antibody specifically binding to the two targets human CD3ε and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.